跳至主要内容
临床试验/NCT04310189
NCT04310189已完成不适用

The Role of IL-22/IL-22BP Axis in Atopic Dermatitis. A Cross Sectional Monocentric Pilot Study

Nantes University Hospital1 个研究点 分布在 1 个国家目标入组 45 人开始时间: 2020年12月2日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
45
试验地点
1
主要终点
Expression levels of IL-22 at the transcriptomic level

研究概览

简要总结

Interleukin 22 (IL-22) is known to be regulated by IL-22 binding protein (IL-22BP), a soluble, inhibitory receptor. The potential role of IL-22BP in atopic dermatitis (AD) is mostly unknown and deserves further investigation. The main objective of this study is to better understand the potential protective role of IL-22BP through the assessment of its expression at the Messenger Ribonucleic Acid (mRNA) and protein levels in skin and serum which will be correlated to the severity of the diseases and through the identification of its cellular sources in lesions. The results of this study will help to correctly interpret the levels of IL-22 in AD and will potentially allow identifying biomarkers for patient stratification and predicting clinical outcomes to targeted therapeutic agents.

详细描述

This is a single-visit study. All patients will have a blood sample and 2 skin biopsies (2 mm diameter) in lesional and non lesional area

. It is planned to include 45 patients (15 patients per severity group: SCORAD ]25-50] , ]50-65]; 50-65; >65).The first 20 patients included will be group 2 and 3 patients (SCORAD > 50).

The patients will be adults with AD recruited from the cohort of patients followed up in the Dermatology department of Nantes University Hospital. A refusal rate of 4/5 is expected. Recruitment can therefore be envisaged in 18 months (2.5 patients/month). Patients will be recruited during follow-up consultations or at the first consultation in the department. Recruitment will be coordinated by the clinical research team (CRT). Blood samples will be taken by the CRT Nurse. The skin and blood samples will be sent to the CIMNA/ Immunology Laboratory Nantes University hospital

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Parallel
主要目的
Other
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with AD according to UK Working Party criteria
  • Patients affiliated to French social security system
  • Patients who gave written consent after reading the protocol
  • Moderate to severe AD (SCORAD score>25)
  • Presence of at least one lesional and one non-lesional skin area in the area covered by the clothing
  • No immunosuppressive systemic treatment in progress for at least 3 months or biologics for at least 4 months

排除标准

  • Minor patients
  • Pregnant and/or breastfeeding women
  • Patients under guardianship or tutorship
  • Inability to understand information and instructions
  • Patients undergoing systemic immunosuppressive treatment for at least 3 months or biologics for at least 4 months
  • Patient included in a clinical trial
  • Documented allergy to the anesthetic (xylocain)

结局指标

主要结局

Expression levels of IL-22 at the transcriptomic level

时间窗: 1 day

To compare the expression levels of IL-22 at the transcriptomic level in non lesional and lesional skin between the different groups of AD patients included in the study. Three groups of patients will be defined based on the SCORAD score . The score is out of 103 and is higher the greater the severity of the disease: * Group 1: SCORAD score between \]25-50\] * Group 2: SCORAD between \]50; 65\] * Group 3: SCORAD greater than 65.

次要结局

  • IL-22 expression levels in lesional skin at the protein level(1 day)
  • level of IL22BP gene expression in in lesional and non lesional(1 day)
  • The level of IL-22-induced gene expression in lesional and non-lesional skin(1 day)
  • Locating IL-22 Binding protein (BP)(1 day)
  • Characterizing IL-22 Binding protein (BP)(1 day)
  • expression levels of IL-22BP at the transcriptome level in in lesional skin(1 day)
  • expression levels of IL-22BP at the protein level in lesional(1 day)
  • level of IL22R gene expression in lesional skin(1 day)
  • Level of IL-22BP and IL-22 proteins in serum(1 day)
  • level of IL22 gene expression in lesional and non lesional skin(1 day)
  • the level of IL22 receptor (IL22R ) gene expression in in lesional and non lesional skin(1 day)
  • The level of expression of the following IL-22-induced genes(1 day)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验